Delix
Founded 2019 · 24 employees on LinkedIn · 10 known investors
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds. Its pipeline includes a Phase 2-ready asset and multiple preclinical programs targeting brain health and neuroplasticity.
Also known as Delix Therapeutics
Investors · 10
Company profile
researched Aug 2026Delix Therapeutics is a neuroscience-focused therapeutics company working on a class of compounds it calls neuroplastogens, which are intended to leverage the brain's own capacity to grow and form new connections. The company's stated approach is that healing the physical structure of brain cells can improve mental function across a range of patient needs and conditions, and it describes an aim of producing treatments that are safe, fast acting and long lasting.
The company organizes its work around what it terms a "neuroplastogen engine" for compound discovery and development, supported by published science on the mechanism and effects of neuroplastogens. According to the company, its compounds preclinically induce selective neuroplasticity and rewire specific neural circuits, with the goal of alleviating prevalent neuropsychiatric conditions. Public-facing sections of the company cover its mission and history, team, science, publications, pipeline and investor and media materials.
▸Full profile — market position, technology, go-to-market
Market position
Delix positions itself in brain health therapeutics, presenting neuroplastogens as a new paradigm relative to existing treatments for neuropsychiatric conditions.
Technology
Delix's technology centers on neuroplastogens, a class of compounds designed to act on neuroplasticity — the brain's ability to grow and form connections. The company states that, preclinically, its neuroplastogens induce selective neuroplasticity and rewire precise neural circuits, and it frames this as repairing the physical structure of brain cells in order to improve mental function. Discovery and development activities are described under the company's "neuroplastogen engine."
Go-to-market
The company targets patients with neuropsychiatric and broader brain health conditions.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 4
by search overlap
Companies competing with Delix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
▸Research sources · 1
primary sources listed
- Delixdelixtherapeutics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Delix do?
- Delix Therapeutics develops neuroplastogens, compounds intended to promote neuroplasticity as brain health therapeutics.
- Who are Delix's investors?
- Delix's investors include Artis Ventures, Casa Verde Capital, Noetic, OMX Ventures, PsyMed Ventures, RA Capital, Vertical Venture Partners, Axial VC and 2 more.